Temozolomide

For research use only. Not for use in humans.

目录号:S1237 别名: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。Temozolomide可诱导凋亡并具有抗肿瘤的活性。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 521.97 现货
RMB 574.37 现货
RMB 1411.95 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Temozolomide发表文献69篇:

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。Temozolomide可诱导凋亡并具有抗肿瘤的活性。
特性 Methazolastone是第二代烷化剂。
靶点
DNA replication [1]
(L-1210, L-1210/BCNU cells)
体外研究

Methazolastone引起DNA碱不稳定位点的形成,其在L-1210和L-1210/BCNU细胞系中以相似数量存在,并且以相似比率修复。在L-1210中,methazolastone诱导细胞阻滞在SL-G2-M期,但在L-1210/BCNU中无此作用。[1]对化疗敏感与耐受的细胞(D54-R 和 U87-R)对Methazolastone的敏感性在高氧情况下被显著增强。Methazolastone和高氧均与ERK p44/42 MAPK (Erk1/2)磷酸化的增加相关,但是在D54-R细胞中增加程度较低,表明Erk1/2可能参与高氧与Methazolastone介导的细胞死亡的调节。高氧增强Methazolastone诱导细胞凋亡在GBM细胞中产生的细胞毒性,可能是通过MAPK相关的途径发挥作用。[2] Methazolastone诱导单核细胞中DNA损伤应答通路ATM-Chk2 和ATR-Chk1,导致p53活化。[3]长期Methazolastone暴露导致获得性Methazolastone耐药,并提高miR-21表达。[4] Methazolastone治疗引起内质网(ER)应激,增加GADD153和GRP78蛋白质表达,并减少caspase 12前体蛋白质。Methazolastone通过线粒体损伤和内质网应激依赖机制诱导自吞噬,以保护神经胶质瘤细胞。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NIi3cmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn5d4REPDhiaB?= M2LRPGlEPTB;MUO5MlIx6oDLwsJihKk2Njl3IN88US=> MV[yOVk3ODJ6Mh?=
KellyCis83 M{X0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfPOFghcA>? NWG4RppnUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>? NWn1[41mOjV7NkCyPFI>
SK-N-AS MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS0PEBp NWe0VWRvUUN3ME2yNlcvPzEkgJpCtgKBkTJ{LkG1JO69VQ>? NHy0bXozPTl4MEK4Ni=>
SK-N-ASCis24 NVjZPG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITUZpQ1QCCq NVXRSGF3UUN3ME20PFAvPjEkgJpCtgKBkTFyMT6xOUDPxE1? M2K3NlI2QTZyMkiy
CHP-212 NVz6c2h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfTXXBoPDhiaB?= MXvJR|UxRTdwOUhihKnDueLCiUCuOlkh|ryP NU\rZo5ROjV7NkCyPFI>
CHP-212Cis100 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7wOFghcA>? NFPPOpRKSzVyPUmuOVXjiIoEsfMAjVAvQDhizszN MoPxNlU6PjB{OEK=
U87  M3njS2Z2dmO2aX;uJGF{e2G7 MmHXNVAxKM7:TR?= MXOyOE04OiCq MnP0bY5lfWOnczDEZ3IyKGW6cILld5Nqd25? MorHNlU5ODh6Nki=
LN229 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHWNE02OCEQvF2= M3zHT2lEPTB;MU[g{txO NFryfmMzPTd3MEK3Ny=>
TR-LN229 NGPpeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGwMVUxKM7:TR?= M3HW[mlEPTB;N{eg{txO NFr4S5ozPTd3MEK3Ny=>
U87  MmP3RZBweHSxc3nzJGF{e2G7 MnLNNQKBmzJyMPMAjeK2VQ>? MoTkNlQhcA>? M3jJXIVvcGGwY3XzJGNSKGmwZIXj[YQh[XCxcITvd4l{ MX2yOVY5OTZ4OB?=
U251MG MWrBdI9xfG:|aYOgRZN{[Xl? NIHXV3cyODEEoN88US=> M4nlOFQ5KGh? MWHQRnM> M4jqNIlv\HWlZYOgZZBweHSxc3nz MmDENlU3QDB2NkS=
U87MG NUixSpRRSXCxcITvd4l{KEG|c3H5 NF\HcpkyODEEoN88US=> NI\NWY81QCCq NIL2c25RSlN? NX3ZT5h[cW6mdXPld{BieG:ydH;zbZM> NITlNoEzPTZ6MES2OC=>
U87 NUHwSmNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrGOVAuOzVyIN88US=> MlnoOFjDqGkEoB?= MVjpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> NHL1VmIzPTV3NEKyNy=>
U118  NVLCTW9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrVfIQ2OC1|NUCg{txO NIPWVYE1QMLiaNMg MWHpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> M{iwblI2PTV2MkKz
U87 M{ThfGZ2dmO2aX;uJGF{e2G7 MV6yOVAwOzVyIN88US=> NVTUcFNOPDkEoHlCpC=> NIjSeYtmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? Mnf3NlU2PTR{MkO=
U118  NIDIWINHfW6ldHnvckBCe3OjeR?= MW[yOVAwOzVyIN88US=> NVLXW5NmPDkEoHlCpC=> MYLlcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U> NX60NVJrOjV3NUSyNlM>
U87 M2DORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrYboR7OjVyL{O1NEDPxE1? MXi0POKhcMLi NIn3W5ZqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS|IwVcLiY3;0doVifGWmIIfpeIghXE2[ MoPKNlU2PTR{MkO=
A375 NUC1dpplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXvTmZRPDkEoHlCpC=> MYnJR|UxRTJ4NTFOwG0> NXntS3ByOjV3MkS1OVI>
A2058 M1nRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;jZYJlPDkEoHlCpC=> NXLnT4pOUUN3ME2xNkDPxE1? NHP6fXgzPTV{NEW1Ni=>
M238 NIO4VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi0OnU1QMLiaNMg Mn7DTWM2OD12MDFOwG0> NHz1cFYzPTV{NEW1Ni=>
M249 NVnVV5B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ey[FQ5yqCqwrC= M4DadGlEPTB;MkW0JO69VQ>? NXG1bZk1OjV3MkS1OVI>
M21 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnWeY1iPDkEoHlCpC=> NEnMXZBKSzVyPUKyNUDPxE1? M3q2elI2PTJ2NUWy
U251 MYjDfZRwfG:6aYT5JGF{e2G7 NXzqWWpJOjBizszNxsA> MmnJOFjDqGkEoB?= MU\y[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm M1O0eFI2PDN2M{ix
LN229 NUi3SHlHS3m2b4TvfIl1gSCDc4PhfS=> NY\EXXUzOjBizszNxsA> MXi0POKhcMLi NFTq[Hlz\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk NHzkXmYzPTR|NEO4NS=>
U373MG-LUC M3\TUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVS3NkBp NWrCVGdnUUN3ME62NFAh|ryP NUD2UZN7OjV2M{G5OVM>
U87  NXfMbZV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f1[|I2NTJyMDFOwG0> MYm0POKhcMLi NUO5TI5HcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVvPbolFOjV2MEC3OFU>
U251 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUiyOU0zODBizszN MXm0POKhcMLi Mn65bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFv6N2gzPTRyMEe0OS=>
U251 M1\Tfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLUNVAxNTRyMDFOwG0> M4TyO|czNzl4IHi= MXz0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NEe5ZnEzPTN5NUK3NS=>
U373 NELnVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnHPYc3OTByLUSwNEDPxE1? NVXkXnExPzJxOU[gbC=> NV20SHk3fGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg NVLmSWVkOjV|N{WyO|E>
U343 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PCWVExOC12MECg{txO NF63Z3E4Oi97NjDo MknEeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi MnTBNlU{PzV{N{G=
U87MG-luc2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fGOlExOC12MECg{txO Mnj5O|IwQTZiaB?= MXj0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NEP3fFAzPTN5NUK3NS=>
U87 M3GzfWZ2dmO2aX;uJGF{e2G7 MkHTNlAxKM7:TR?= M{HsZlQ5KGh? MX\pcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v NEPFeJIzPTN|N{eyNS=>
U251 MlzBSpVv[3Srb36gRZN{[Xl? M3vmelIxOCEQvF2= NVXGOYI2PDhiaB?= MYnpcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v MWmyOVM{Pzd{MR?=
A172 NXXKfWp[TnWwY4Tpc44hSXO|YYm= MWqyNFAh|ryP NYDOWWlKPDhiaB?= M4G5S4lv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? M3zMdFI2OzN5N{Kx
U251 MV;GeY5kfGmxbjDBd5NigQ>? NFvLNmozODBizszN M2jF[VQ5KGh? MnPEbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? M1m2e|I2OzN5N{Kx
A172 MVvGeY5kfGmxbjDBd5NigQ>? MoPsNlAxKM7:TR?= MUC0PEBp MWfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz M{m4PVI2OzN5N{Kx
U87 NH3mZolHfW6ldHnvckBCe3OjeR?= MVGyNFAh|ryP M4nRcFI1Nzd{L{GyNEBp M2mzXIlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MYCyOVM{Pzd{MR?=
U251 NWDuenhrTnWwY4Tpc44hSXO|YYm= NYr1dJRpOjByIN88US=> NUTQSIE5OjRxN{KvNVIxKGh? MXzpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> MVqyOVM{Pzd{MR?=
A172 NVjicpNsTnWwY4Tpc44hSXO|YYm= M{HiOFIxOCEQvF2= MomwNlQwPzJxMUKwJIg> NULjb4ZJcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 MnnKNlU{Ozd5MkG=
SNB19V NVLBZ2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TIdVch\A>? Mn;kSG1UVw>? M4HsO2dKPTB;M{WuO:KyOTJizszN M1HlWFI2Ojd5NESx
SNB19M NEfPNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvPXItPPyCm MXPEUXNQ NULsVZRzT0l3ME20OlkvQcLzOEig{txO Mn71NlUzPzd2NEG=
SNB19VR M2jMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\wfFch\A>? NGnEeHpFVVOR NEDtZ4dIUTVyPUK4NE4zyrFzODFOwG0> MmrzNlUzPzd2NEG=
U373V Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33zU|ch\A>? MWPEUXNQ MUfHTVUxRTZ6LkFCtVMzKM7:TR?= MVOyOVI4PzR2MR?=
U373M M4TRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3JIQ> M3vQTWROW09? MorRS2k2OD1|NkiuO:KyQDZizszN MnPLNlUzPzd2NEG=
U373VR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fBdFch\A>? NILJZ5pFVVOR MYXHTVUxRTJ6OD64xtE{OyEQvF2= M4DLZVI2Ojd5NESx
U87MG M1zjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVG3JIQ> MkDiSG1UVw>? MV\HTVUxRTN6LkRCtVIxKM7:TR?= NWrHWJdDOjV{N{e0OFE>
HCT116 NIXQdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF20d3k4KGR? M3v6NWROW09? MVTHTVUxRTV5OT65xtE{OiEQvF2= MlXVNlUzPzd2NEG=
DLD1 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXuRXd4PyCm NVXtNYZZTE2VTx?= Mn7vS2k2OD13MEGuOOKyQTNizszN MXKyOVI4PzR2MR?=
MRC5 NF61fYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3CcGQ4KGR? MVjEUXNQ NHLjNWpIUTVyPUS0PU41yrF6IN88US=> NYD2elkzOjV{N{e0OFE>
SNB19V  NWflRWJMTnWwY4Tpc44hSXO|YYm= MnfiNVAxKM7:TdMgWG1b NGm2cVkxNTd{IHi= Ml;UbY5kemWjc3XzJO6{UDKDWDDlfJBz\XO|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg> MoHjNlUzPzd2NEG=
T98G  NULjOohOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O3WVUwOTBxMUWg{txO M4rJeVI1yqCq MXTpcoR2[2W|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?= Mn;yNlUzPjJ7NkG=
U251  MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TXdlUwOTBxMUWg{txO NVfYVnBKOjUEoHi= NU\0XG1ucW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ> NHPHNlYzPTJ4Mkm2NS=>
T98G  NGLPb5dHfW6ldHnvckBCe3OjeR?= MmWzNVUh|ryP MlzLNlTDqGh? MVHpcoNz\WG|ZYOgSG5CNW[{YXft[Y51[XSrb36gbY4hVlCnNj3QSHQhfHKnYYTl[EBodGmxbXGgZ4VtdHN? MlTrNlUzPjJ7NkG=
U251  NUHMfGhqTnWwY4Tpc44hSXO|YYm= NHP2SXIyPSEQvF2= NITmR40zPMLiaB?= NUPwXoJ2cW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz NYPQOIpUOjV{NkK5OlE>
U-87 MG M4rodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV63NkBp MWHJR|UxRTBwOUOgcW3DqA>? M{XwUVI2OjR3M{Oy
U-118 MG NI\tOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLhXGw4OiCq M4W4cGlEPTB;MT6wOUBuVcLi NHnKdG8zPTJ2NUOzNi=>
U87 M4PLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiyOEBp M3nZSWlEPTB;Mk[wMlM1KM7:TdMg NIi2NpQzPTF5M{KzNy=>
U87 GSLCs NVfPNmM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuyOEBp NV;R[JhnUUN3ME23OlYvOTFizszNxsA> M2O1VlI2OTd|MkOz
U87MG MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK3NkBp M171dWlEPTB;MUWuOlI2KM7:TdMg MUWyOVA2ODlzNR?=
U251 NVe5eoh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDSS2IyODBvNECwJO69VQ>? MlzXOFghcA>? NG\lbIJFVVOR NUjQOopZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MViyOFYzOzd|Nh?=
U87 NVTsbnZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe1TlgzOTByLUSwNEDPxE1? NUfvNXB7PDhiaB?= MYPEUXNQ MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHXNVHIzPDZ{M{ezOi=>
MDA-MB-231-br NFi5PWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfQTpdiOC1zMDFOwG0> M1jPTVQ5KGh? NXy3NWxTTE2VTx?= M4jTW4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVWyOFYzOzd|Nh?=
HCC-1937 NH3iN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jGOFAuOzByIN88US=> M1fa[lQ5KGh? MWnEUXNQ NYP4[VFScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoG2NlQ3OjN5M{[=
MDA-MB-231 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWruSZRsOC12MDFOwG0> NYTMUWRDPDhiaB?= NFftcW1FVVOR MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUOyOFYzOzd|Nh?=
MDA-MB-468 NHvqSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTxNE02ODBizszN NXzncJhwPDhiaB?= NFfHR29FVVOR NVzhdXY1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUCyOFYzOzd|Nh?=
T47D NXHZVoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7DNE0yODBizszN M4D2bVQ5KGh? NFXMSm9FVVOR NXrlRVNvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHjJ[|EzPDZ{M{ezOi=>
MCF7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPCNE0yODByIN88US=> MofQOFghcA>? MVnEUXNQ NFfwN41qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmTjNlQ3OjN5M{[=
Hs683 M2PjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjQZnROOC1zMECwJO69VQ>? NVPiVGJvQTZiaB?= M3TocGlEPTB;MUK4Mlkh|ryP MWWyOFQ6PTlyNx?=
U87 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPONE0yODByIN88US=> NXfC[INmQTZiaB?= M4nCZ2lEPTB;MUiuOFUh|ryP MUeyOFQ6PTlyNx?=
LNZ308 NG\u[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWiwMVExODBizszN NHzTbJA6PiCq M3LFR2lEPTB;M{K2Mlch|ryP M{PuTFI1PDl3OUC3
U87 MUDBdI9xfG:|aYOgRZN{[Xl? M1P0[lExOCEQvF2= M4\nVVQ5KGh? MWrEUXNQ NUDLO29TcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> MYGyOFQ5OTV6Nh?=
U251  Mo\NRZBweHSxc3nzJGF{e2G7 M3;uelExOCEQvF2= NXS2Z25uPDhiaB?= MnXpSG1UVw>? NISzSoFqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 NFjMTFczPDR6MUW4Oi=>
U251 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv4dY1XOjRiaB?= NYrQV3BPUUN3ME24Ok4zQeLCidMx5qCKOS53ODFOwG0> NWHDRWo4OjR|Mk[5OVQ>
U251 MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT3OFghcA>? MnrXTWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= NITNXHczPDN{Nkm1OC=>
U251 M3;aWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7Depk4OiCq MnvqTWM2OD15Mj60NwKBkcLz4pEJNU41PSEQvF2= MUGyOFMzPjl3NB?=
U251 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnjfXN4QTZiaB?= MX3JR|UxRTZ7Lkiy5qCKyrIkgJmzMlA1KM7:TR?= MmPkNlQ{OjZ7NUS=
T98G NHG4WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrkS|IxNTd3MDFOwG0> NYjxSXVuPzJxOU[gbC=> NFzWT5dqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MnPaNlQ{OjRyOEC=
U251-MG MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWwMVgxOCEQvF2= MV:3NkBp NWnKWJhkcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NGTwe2wzPDB7M{[zNC=>
D54-MG NWXvcWJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjyRnAxNThyMDFOwG0> M1;GelczKGh? MXTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUWyOFA6OzZ|MB?=
SHG-44 MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK5S2kyOC1{MECg{txO MVK5OkBp MYTJR|UxRTlwN{OgxtEhOi5zMjFOwG0> M1HPclI1ODZ3NU[5
U373  MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DxPFExNTJyMDFOwG0> NWrPUnZ4QTZiaB?= Mn\5TWM2OD1zMD6xN{DDuSBzLkCyJO69VQ>? NHnqfJczPDB4NUW2PS=>
HT-29  NHrrUZJHfW6ldHnvckBCe3OjeR?= NYj6NHc6PTByIN88US=> M2PyeFI1NzR6IHi= MnnS[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB? M2LOb|I1ODN6ME[4
PC-3  Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17TdVAuOjVizszN M3jBOVQ5KGh? M2f4colvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDwc5RmdnSrYYTl[EBjgSCueXPvdIVv\Q>? MlXYNlM4PDZ7M{S=
PC-3  M{TxTWFxd3C2b4Ppd{BCe3OjeR?= M1TNZlI2KM7:TR?= NWm5co9oPDhiaB?= MWjpcoR2[2W|IHHwc5B1d3OrczD3bIlkcCClYX6gZoUheG:2ZX70bYF1\WRiYomgcJlkd3CnbnW= NITqZ5czOzd2NkmzOC=>
T98G MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG1NE01ODBizszN NWi2VmZHOTR2IHi= M3zrSIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFzPWIgzOzdzNUS5PS=>
U87-MG M1rseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\2RVExOCEEtV2= Ml;GO|IhcA>? MWHpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgS3RD M2\SWlI{Pjl4N{i4
U251-MG NXnpWJlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ntd|ExOCEEtV2= MV23NkBp NWXI[JBKcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= M{fWfVI{Pjl4N{i4
LNT-229 NXrMbWpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK3TYVJOy1zMECg{txO Mn3BNlQhcA>? MVTpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NX;H[GZQOjN4Nke2N|I>
T98G NUHLbHRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M171VFExNTdyMDFOwG0> NFXnfnkzPCCq NWraOHBmcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWSyN|Y3PzZ|Mh?=
U87  M1XCfWZ2dmO2aX;uJGF{e2G7 MUexNFAhyrWP MnrHN{Bp MXrlcIV3[XSnczD0bIUhdGW4ZXzzJI9nKHCFaHuxJIFv\CCyQ3jrNi=> M1fZO|I{PjZ5NE[5
HCT116 MnzRSpVv[3Srb36gRZN{[Xl? NXnX[W5nOTByINM1US=> NVvtS2d2OyCq MkfhbY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? NUP3SFFPOjN4Nke0Olk>
HCT3-6 MoK3SpVv[3Srb36gRZN{[Xl? NGf4WW4yODBiwsXN MUWzJIg> NWPE[mNVcW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= MWSyN|Y3PzR4OR?=
U-87  MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vyZ|AuPDBizszN M2rWe|EzKGR? MoTJbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIXwb2EzOzZ2NUeyPS=>
U-87  NWf4V49XSXCxcITvd4l{KEG|c3H5 NGS1ZWsxNTRyIN88US=> MXKzM|Yh\A>? MUfpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M1XvelI{PjR3N{K5
U-87  NED6NXdHfW6ldHnvckBCe3OjeR?= NEG3T5cxNTRyIN88US=> MVOzM|Yh\A>? M1rVUolv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MUCyN|Y1PTd{OR?=
GB-SCC010 NWqybHpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXERZM1KGR? NHj2UpZKSzVyPUKyOkDPxE1? NFnJTGwzOzZzMke1OS=>
GB-SCC026 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\uOmg1KGR? NH3qZZFKSzVyPUWzMlEh|ryP Mn7wNlM3OTJ5NUW=
GB-SCC028 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUG0JIQ> MnnsTWM2OD1zNkeg{txO NEixUW4zOzZzMke1OS=>
U87 M2TrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\hOlQh\A>? M{\CUGlEPTB;NEWuNkDPxE1? NYmzOmx4OjN4MUK3OVU>
U87 stem cell M1XmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fqOFQh\A>? NHzofJpKSzVyPU[2Mlch|ryP NGjXXWQzOzZzMke1OS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
体内研究 每天腹腔注射40 mg/kg,连续5天(肿瘤移植后1-5天)后,在L-1210 和L-1210/BCNU中,methazolastone分别增加86%和22%的寿命。在L-1210/BCNU中,100 μM 或200 μM治疗后没有作用,仅400 μM methazolastone使细胞在有丝分裂前期产生积聚,但是在L-1210中效果较弱。在L-1210/BCNU中,SL-G2-M期细胞的最大积聚在48-72小时后,大约为30%,未处理的细胞为23%。患有L- 1210白血病的小鼠静脉注射methazolastone (40 mg/kg)时,也会使细胞在SL-G2-M期积聚。而给予相同剂量药物的小鼠L-1210/BCNU细胞中,没有此作用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: L-1210 和 L-1210/BCNU 细胞
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 1小时
  • Method:

    L-1210和L-1210/ BCNU细胞以0.2×104 cells/mL接种,并培养24小时。培养基用Methazolastone在37℃下处理1小时,然后用PBS洗涤两次,离心并重新悬浮在新鲜培养基中。对照组和处理试样在48小时时以1:4在新鲜培养基中稀释,第96小时时,以1:2稀释。整个实验中使用这些稀释的细胞浓度介于3×105和8×105/mL之间。该范围内对照组呈对数生长。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 负荷L-1210 和 L-1210/BCNU细胞的DBA/2小鼠
  • Dosages: 40 mg/kg
  • Administration: 静脉注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 194.15
化学式

C6H6N6O2

CAS号 85622-93-1
储存条件 粉状
溶于溶剂
别名 CCRG81045, NSC 362856

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04238819 Not yet recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company July 31 2020 Phase 1
NCT04388475 Not yet recruiting Drug: OKN-007|Drug: Temozolomide (TMZ) Recurrent Malignant Glioma|Brain Glioblastoma Oblato Inc. May 25 2020 Phase 2
NCT03796507 Not yet recruiting Drug: Temozolomide Glioma of Brain University of Rochester|National Institutes of Health (NIH) March 1 2020 Early Phase 1
NCT04200066 Not yet recruiting Drug: Temozolomide Tamoxifen Maprotiline Glioblastoma|Brain Tumor University of Rochester February 1 2020 Phase 1
NCT04091503 Not yet recruiting Drug: Intranasal Modified Temozolomide Glioma Malignant|Gliosarcoma|Astrocytoma of Brain Center Trials & Treatment Europe December 10 2019 Phase 1
NCT03932981 Recruiting Drug: Temozolomide Adult Brainstem Glioma Assistance Publique - Hôpitaux de Paris July 26 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Temozolomide | Temozolomide ic50 | Temozolomide价格 | Temozolomide DMSO溶解度 | 采购Temozolomide | Temozolomide生产 | Temozolomide 小鼠 | Temozolomide化学结构 | Temozolomide分子量 | Temozolomide molecular weight | Temozolomide说明书 | Temozolomide供应商 | Temozolomide体内 | Temozolomide细胞系 | Temozolomide浓度 | Temozolomide nmr | Temozolomide核磁 | Temozolomide半数抑制浓度 | Temozolomide体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID